Jean Jacques Bienaime net worth and biography

Jean Bienaime Biography and Net Worth

Jean Jacques Bienaime is the chairman and CEO at BioMarin, a world leader in developing and commercializing first- or best-in-class therapies for rare genetic diseases.

Bienaimé joined BioMarin in 2005 as CEO and a member of the board of directors, bringing more than 25 years of biotechnology and pharmaceutical experience. He is credited with the company’s significant growth in revenue, employees, and stature. Under his direction, BioMarin’s market capitalization went from approximately $450 million to around $14 billion.

Prior to BioMarin, Bienaimé was the chairman, CEO, and president of Genencor, a leading biotechnology company and a pioneer in enzyme innovation.

During his tenure, the company’s revenues experienced a significant increase to more than $400 million, and in 2005, it was sold to Danisco at an enterprise value of more than $1.2 billion.

Before Genencor, Bienaimé was the chairman, CEO, and president of Sangstat Medical Corporation, where he managed revenue growth, bringing it to profitability before it was acquired by Genzyme Corporation.

Previously, he held senior management roles at Rhone-Poulenc Rorer Pharmaceuticals (now SanofiAventis), including senior vice president of worldwide marketing and business development. In this role, he was responsible for the U.S. launch of Lovenox® and the global launch of Taxotere®. He also worked for Genentech, Inc. where he was involved with the launch of tissue plasminogen activator (t-PA).

Bienaimé currently sits on the board of Incyte Corporation, as well as those of industry trade organizations, PhRMA and Biotechnology Innovation Organization (BIO). He has previously served on the boards of Portola Pharmaceuticals, Inc., InterMune, Inc., and Vital Therapies, Inc., among others.

In 2020, he was recognized as one of The Healthcare Technology Report’s “Top 50 Healthcare Technology CEOs.”

Bienaimé earned a degree in economics at the École Supérieure de Commerce de Paris and an M.B.A. from the Wharton School at the University of Pennsylvania

What is Jean Jacques Bienaime's net worth?: The estimated net worth of Jean Jacques Bienaime is at least $1.04 million as of August 16th, 2024. Mr. Bienaime owns 16,615 shares of BioMarin Pharmaceutical stock worth more than $1,039,434 as of November 21st. This net worth evaluation does not reflect any other investments that Mr. Bienaime may own. Learn More about Jean Jacques Bienaime's net worth.
How do I contact Jean Jacques Bienaime?: The corporate mailing address for Mr. Bienaime and other BioMarin Pharmaceutical executives is 770 Lindaro Street, San Rafael CA, 94901. BioMarin Pharmaceutical can also be reached via phone at (415) 506-6700 and via email at [email protected]. Learn More on Jean Jacques Bienaime's contact information.
Has Jean Jacques Bienaime been buying or selling shares of BioMarin Pharmaceutical?: Jean Jacques Bienaime has not been actively trading shares of BioMarin Pharmaceutical in the last ninety days. Most recently, Jean Jacques Bienaime sold 20,000 shares of the business's stock in a transaction on Thursday, May 9th. The shares were sold at an average price of $81.62, for a transaction totalling $1,632,400.00. Following the completion of the sale, the director now directly owns 474,994 shares of the company's stock, valued at $38,769,010.28. Learn More on Jean Jacques Bienaime's trading history.
Who are BioMarin Pharmaceutical's active insiders?: BioMarin Pharmaceutical's insider roster includes Jeffrey Ajer (EVP), Mark Alles (Director), Jean Bienaime (CEO), George Davis (EVP), Willard Dere (Director), Henry Fuchs (Insider), Michael Grey (Director), Charles Guyer (EVP), V. Lawlis (Director), Richard Meier (Director), Brian Mueller (CFO), David Pyott (Director), and Dennis Slamon (Director). Learn More on BioMarin Pharmaceutical's active insiders.
Are insiders buying or selling shares of BioMarin Pharmaceutical?: In the last twelve months, insiders at the biotechnology company sold shares 16 times. They sold a total of 209,971 shares worth more than $17,856,129.12. The most recent insider tranaction occured on November, 12th when EVP Charles Greg Guyer sold 5,278 shares worth more than $350,300.86. Insiders at BioMarin Pharmaceutical own 1.9% of the company. Learn More about insider trades at BioMarin Pharmaceutical.
Information on this page was last updated on 11/12/2024.

Jean Jacques Bienaime Insider Trading History at BioMarin Pharmaceutical

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/9/2024	Sell	20,000	$81.62	$1,632,400.00	474,994
4/12/2024	Sell	20,000	$91.26	$1,825,200.00	474,994
3/5/2024	Sell	1,000	$85.51	$85,510.00	561,203
2/27/2024	Sell	1,000	$90.35	$90,350.00	562,203
2/9/2024	Sell	15,000	$88.28	$1,324,200.00	419,602
1/9/2024	Sell	10,000	$98.19	$981,900.00	425,162
12/21/2023	Sell	10,000	$93.99	$939,900.00	425,112
8/7/2023	Sell	4,000	$88.10	$352,400.00	428,732
5/10/2023	Sell	30,000	$94.85	$2,845,500.00	426,213
4/10/2023	Sell	10,000	$99.56	$995,600.00	425,896
4/6/2023	Sell	10,000	$96.13	$961,300.00	425,896
3/13/2023	Sell	8,000	$90.45	$723,600.00	487,856
3/10/2023	Sell	15,000	$92.28	$1,384,200.00	487,856
2/13/2023	Sell	6,000	$109.15	$654,900.00	320,324
2/10/2023	Sell	15,000	$110.11	$1,651,650.00	320,324
1/17/2023	Sell	10,000	$111.55	$1,115,500.00	320,424
1/13/2023	Sell	10,000	$112.25	$1,122,500.00	320,424
12/13/2022	Sell	1,000	$106.89	$106,890.00	320,424
12/2/2022	Sell	1,500	$103.98	$155,970.00	321,424
10/31/2022	Sell	1,500	$86.55	$129,825.00	322,824
10/14/2022	Sell	4,000	$89.89	$359,560.00	324,324
8/15/2022	Sell	3,000	$95.21	$285,630.00	328,324
8/12/2022	Sell	4,000	$94.75	$379,000.00	331,324
5/5/2022	Sell	10,000	$84.14	$841,400.00	335,324
4/28/2022	Sell	20,000	$83.79	$1,675,800.00	334,983
4/18/2022	Sell	20,000	$81.91	$1,638,200.00	334,983
4/14/2022	Sell	10,000	$83.66	$836,600.00	334,983
3/10/2022	Sell	15,000	$77.57	$1,163,550.00
1/13/2022	Sell	5,000	$87.86	$439,300.00
12/15/2021	Sell	6,000	$82.71	$496,260.00
12/1/2021	Sell	1,500	$87.22	$130,830.00
5/10/2021	Sell	8,513	$77.29	$657,969.77	312,352
5/7/2021	Sell	25,000	$78.12	$1,953,000.00	303,839
4/23/2021	Sell	10,000	$79.34	$793,400.00	312,498
3/11/2021	Sell	7,000	$77.68	$543,760.00	295,652
2/19/2021	Sell	7,000	$83.58	$585,060.00	302,552
2/17/2021	Sell	8,000	$84.54	$676,320.00	303,552
1/29/2021	Sell	8,334	$82.67	$688,971.78	303,885
1/27/2021	Sell	8,333	$85.49	$712,388.17	303,885
12/28/2020	Sell	1,500	$88.77	$133,155.00	297,052
5/8/2020	Sell	20,000	$91.72	$1,834,400.00	318,552
5/4/2020	Sell	5,000	$88.00	$440,000.00	298,552
5/1/2020	Sell	4,000	$89.38	$357,520.00	298,552
4/28/2020	Sell	20,000	$97.58	$1,951,600.00	318,213
4/9/2020	Sell	10,000	$79.06	$790,600.00	308,213
3/9/2020	Sell	10,000	$89.52	$895,200.00	296,443
1/14/2020	Sell	8,000	$87.95	$703,600.00	335,530
1/7/2020	Sell	3,000	$84.46	$253,380.00	330,530
12/27/2019	Sell	5,000	$86.16	$430,800.00
11/22/2019	Sell	10,000	$77.60	$776,000.00	327,070
10/25/2019	Sell	5,000	$69.55	$347,750.00	332,520
5/10/2019	Sell	10,000	$82.52	$825,200.00	336,520
5/8/2019	Sell	4,000	$82.16	$328,640.00	326,520
4/26/2019	Sell	3,000	$82.88	$248,640.00	329,211
4/12/2019	Sell	4,000	$89.12	$356,480.00	325,211
4/8/2019	Sell	3,000	$91.87	$275,610.00	327,211
4/5/2019	Sell	3,000	$93.37	$280,110.00	327,211
3/25/2019	Sell	4,000	$87.86	$351,440.00	323,211
3/15/2019	Sell	4,000	$94.40	$377,600.00	300,558
3/12/2019	Sell	9,000	$90.06	$810,540.00	333,701
3/7/2019	Sell	4,000	$90.78	$363,120.00	332,701
2/27/2019	Sell	4,000	$91.78	$367,120.00	292,290
2/21/2019	Sell	3,000	$90.12	$270,360.00	291,290
2/14/2019	Sell	4,000	$95.20	$380,800.00	292,290
2/5/2019	Sell	4,000	$98.63	$394,520.00	292,290
1/22/2019	Sell	3,000	$96.82	$290,460.00	291,290
1/14/2019	Sell	4,000	$93.79	$375,160.00	292,290
1/10/2019	Sell	3,000	$90.55	$271,650.00	291,290
1/7/2019	Sell	3,000	$87.58	$262,740.00	291,290
12/28/2018	Sell	3,000	$84.04	$252,120.00
12/28/2018	Sell	3,000	$84.04	$252,120.00	291,290
12/26/2018	Sell	4,000	$80.50	$322,000.00	292,290
12/14/2018	Sell	2,000	$92.64	$185,280.00	290,290
12/12/2018	Sell	2,000	$93.12	$186,240.00	290,290
11/1/2018	Sell	4,000	$92.55	$370,200.00	292,290
10/3/2018	Sell	1,500	$99.36	$149,040.00	287,790
9/4/2018	Sell	1,500	$98.16	$147,240.00	286,790
7/23/2018	Sell	1,500	$101.69	$152,535.00	286,790
5/17/2018	Sell	18,750	$88.66	$1,662,375.00	309,350
5/15/2018	Sell	37,500	$88.75	$3,328,125.00	309,350
5/11/2018	Sell	18,750	$88.42	$1,657,875.00
4/24/2018	Sell	20,000	$82.43	$1,648,600.00	300,031
4/20/2018	Sell	10,000	$83.65	$836,500.00	300,031
3/15/2018	Sell	15,000	$84.73	$1,270,950.00	279,674
2/15/2018	Sell	10,000	$84.63	$846,300.00
1/5/2018	Sell	10,000	$90.32	$903,200.00	235,894
12/29/2017	Sell	20,000	$89.75	$1,795,000.00
12/29/2017	Sell	10,000	$89.61	$896,100.00	226,494
6/5/2017	Sell	10,000	$90.13	$901,300.00	238,564
5/24/2017	Sell	5,000	$88.38	$441,900.00	238,564
5/17/2017	Sell	5,000	$91.73	$458,650.00	238,564
5/8/2017	Sell	10,000	$96.09	$960,900.00	238,496
4/27/2017	Sell	5,000	$95.72	$478,600.00	243,194
4/25/2017	Sell	5,000	$94.00	$470,000.00	243,194
3/16/2017	Sell	10,000	$91.69	$916,900.00	211,364
3/10/2017	Sell	11,000	$90.59	$996,490.00	212,364
1/26/2017	Sell	10,000	$84.22	$842,200.00	175,682
1/11/2017	Sell	8,000	$90.58	$724,640.00	174,682
1/9/2017	Sell	8,000	$88.49	$707,920.00	174,682
12/30/2016	Sell	8,000	$83.60	$668,800.00	174,682
11/22/2016	Sell	69,743	$85.69	$5,976,277.67
11/21/2016	Sell	69,744	$87.56	$6,106,784.64
11/8/2016	Sell	140,000	$82.67	$11,573,800.00	393,368
11/7/2016	Sell	70,000	$82.52	$5,776,400.00	393,368
10/28/2016	Sell	120,000	$81.30	$9,756,000.00	383,368
10/17/2016	Sell	41,666	$84.39	$3,516,193.74	365,034
10/14/2016	Sell	64,125	$86.96	$5,576,310.00	378,184
9/29/2016	Sell	53,125	$93.65	$4,975,156.25	431,709
9/16/2016	Sell	137,368	$95.34	$13,096,665.12	421,161
8/16/2016	Sell	41,666	$91.49	$3,812,022.34	420,250
7/18/2016	Sell	41,666	$92.72	$3,863,271.52	420,250
6/16/2016	Sell	41,666	$80.55	$3,356,196.30	420,250
5/5/2016	Sell	50,000	$80.15	$4,007,500.00	390,156
5/2/2016	Sell	36,500	$85.01	$3,102,865.00	395,635
3/1/2016	Sell	10,000	$84.28	$842,800.00	350,500
11/30/2015	Sell	1,000	$94.74	$94,740.00	228,754
10/15/2015	Sell	1,000	$108.24	$108,240.00	228,754
9/14/2015	Sell	1,000	$131.43	$131,430.00	228,754
7/7/2015	Sell	1,500	$139.07	$208,605.00
3/17/2015	Sell	2,000	$124.17	$248,340.00
3/16/2015	Sell	1,000	$123.48	$123,480.00
3/10/2015	Sell	21,021	$112.39	$2,362,550.19
3/9/2015	Sell	19,000	$112.13	$2,130,470.00
3/5/2015	Sell	10,000	$113.70	$1,137,000.00
3/4/2015	Sell	13,916	$107.92	$1,501,814.72
3/3/2015	Sell	5,000	$107.42	$537,100.00
3/2/2015	Sell	5,000	$108.44	$542,200.00
1/9/2015	Sell	2,000	$94.14	$188,280.00
12/24/2014	Sell	5,000	$88.73	$443,650.00
12/10/2014	Sell	2,000	$95.00	$190,000.00
11/25/2014	Sell	2,000	$90.00	$180,000.00
11/12/2014	Sell	1,000	$81.51	$81,510.00
11/10/2014	Sell	4,000	$87.00	$348,000.00
11/3/2014	Sell	3,000	$85.33	$255,990.00
10/24/2014	Sell	2,000	$80.00	$160,000.00
8/20/2014	Sell	5,000	$70.00	$350,000.00
6/4/2014	Sell	2,000	$61.20	$122,400.00
5/22/2014	Sell	1,000	$56.88	$56,880.00	180,257
5/21/2014	Sell	1,545	$56.19	$86,813.55	180,257
12/24/2013	Sell	10,000	$68.71	$687,100.00
12/5/2013	Sell	5,000	$69.70	$348,500.00
10/16/2013	Sell	2,000	$67.73	$135,460.00
10/10/2013	Sell	3,000	$66.76	$200,280.00
9/16/2013	Sell	2,000	$73.08	$146,160.00
8/15/2013	Sell	1,000	$64.36	$64,360.00
5/21/2013	Sell	2,000	$64.14	$128,280.00
5/16/2013	Sell	12,000	$67.90	$814,800.00
5/14/2013	Sell	15,000	$70.17	$1,052,550.00
5/13/2013	Sell	15,800	$68.77	$1,086,566.00
5/8/2013	Sell	4,000	$65.87	$263,480.00
5/2/2013	Sell	3,000	$64.99	$194,970.00
2/4/2013	Sell	2,000	$55.77	$111,540.00
12/27/2012	Sell	17,000	$48.37	$822,290.00

Jean Jacques Bienaime Buying and Selling Activity at BioMarin Pharmaceutical

BioMarin Pharmaceutical Company Overview

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Today's Range

Now: $62.56

$61.61

$62.70

50 Day Range

MA: $69.08

$61.93

$84.90

2 Week Range

Now: $62.56

$61.15

$99.56

Volume

1,245,536 shs

Average Volume

1,829,197 shs

Market Capitalization

$11.92 billion

P/E Ratio

37.46

Dividend Yield

N/A

Beta

0.31

📉 Warning: Market Crash Predicted - Secure Your Savings

From Behind the Markets | Ad

The last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.

Take these 4 steps to protect your retirement here >>>